Arming an Anti-CD38 Antibody With Interferon in Myeloma
James R. Berenson, MD, discusses a study presented at the 2013 American Society of Hematology (ASH) Meeting that looked at arming an anti-CD38, myeloma-targeting antibody with interferon.
Clinical Pearls
James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, discusses a study presented at the 2013 American Society of Hematology (ASH) Meeting that looked at arming an anti-CD38, myeloma-targeting antibody with interferon.
- Interferon was used to treat myeloma (maintain remissions) in the 1980s and 1990s
- When paired with interferon, this anti-CD38 agent can enhance tumor-specific activity 10,000x compared with native interferon
- This pairing cured multiple tumors in mice
- It remains unknown if this pairing will have effects on immune and other cells in the human body
<<<
Functional High Risk and Bridging in Multiple Myeloma Considered With CAR T Cells
October 9th 2024Samer A. Al'Hadidi, MD, MS, reviewed the benefits of cilta-cel in the subgroup analysis of CARTITUDE-4 in patients with relapsed/refractory multiple myeloma and functional high risk, bridging to cilta-cel, and time to treatment in the second article of a 2-part series.
Read More
